Prelude Therapeutics Incorporated
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
79.8M
on 2026-08-06, from 54.9M on 2024-05-01 10-Q ↗
a raise that quarter, at its price
Newest
S-3 of 2024-05-30. Not read yet. S-3 ↗
$25.0M
Jefferies, agreement of 2026-03-12. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-11 is not read yet.
Cash
18.3 quarters
$151.8M on 2026-06-30 ÷ $8.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-04-20 | Public offering incl. 2.25M pre-funded | 20,270,266 | $4.44 | $90.0M | 424B5 ↗ |
| 2025-11-04 | Private placement | 6,250,000 | $4.00 | not stated | 8-K ↗ |